摘要
目的：观察平消胶囊对手术后Ⅰ～Ⅱa期非小细胞肺癌的l、3年生存率，免疫功能及生存质量的影响。方法：全部患者均经病理证实的非小细胞肺癌。根据临床和术后病理确定为Ⅰ～Ⅱa期，Karnofsky评分≥70分，年龄在35-75岁。治疗组术后两周给予平消胶囊治疗，一次4～5粒，3次／d，90d为一疗程，对照组术后不给予任何治疗。治疗结束后对两组病人的1、3年生存率，免疫功能及生存质量进行评估。结果：治疗组1、3年生存率分别为95．5％、66．5%；对照组为94．0％、64．5％。两组1、3年生存率差异无显著性（P〉0．05），治疗组外周血T细胞亚群、T淋巴细胞的比值明显高于对照组（P〈0．05）。生存质量（生活质量调查、体重、卡氏评分）明显高于对照组（P〈0．05）。结论：平消胶囊具有增加患者免疫力及提高生存质量的作用，但对术后Ⅰ～Ⅱa期非小细胞肺癌的生存率（1、3年生存率）无明显影响。
Objective： To investigate the survival rate in one and three years,the immunity and living quality while the Ⅰ～Ⅱ a NSCLC patients were treated with Pingxiao Capsule after operation. Methods： The patients confirmed suffering from non small cell lung cancer（NSCLC） were diagnosed being in the Ⅰ～Ⅱ a period,Karnofsky≥70,35-70 years old （including 35 and 75）. The group was treated with Pingxiao Capsule,4 -5 capsules pertime,three times a day,taking 90 days as treating course,but the control group didn＇t receive any treatment. After the treatment ended, the survival rate, immunity and living quality were evaluated. Results：For the treated group,the survival rates for one and three years were 95.5% and 66.5% separately. For the control group,the rates of that were 94. 0% and 64.5%. There is no significant differece between the two groups（P〉0.05）. The specific data of outside T-cell submass and limphcell in the treated group was higher than that of the control group（P〈0.05）. The treated group＇s living quality（living quality form of questionnaire, weight,calculative mark） was higher than that of the control group（P〈0.05）. Conclusion：Pingxiao Capsule has the function to improve patient＇s immunity and living quality. But there is no remarkable affect on survival rate of the patients suffering from non-small cell lung cancer after operation.
出处
《河北北方学院学报（医学版）》
2006年第4期34-35,共2页
Journal of Hebei North University:Medical Edition
